CMV DNAemia in Hospitalized Adults with COVID-19 Requiring Oxygen Support

Overview

In hospitalized adults with COVID-19 requiring oxygen, CMV DNAemia occurred in 11% of CMV-seropositive patients by day 28 and was associated with older age, male sex, lymphopenia, and corticosteroid use. CMV DNAemia independently correlated with delayed clinical recovery, higher SARS-CoV-2 viral loads, and increased mortality.

Background

Cytomegalovirus (CMV) reactivation has been observed in critically ill patients and may worsen outcomes by modulating immune responses and causing organ damage. COVID-19 severity and mortality are higher in older adults and those with comorbidities, populations with increased CMV seroprevalence. Severe SARS-CoV-2 infection induces immunosuppression and cytokine dysregulation, potentially triggering CMV reactivation. Understanding CMV DNAemia kinetics and its impact on COVID-19 outcomes is critical for managing hospitalized patients.

Data Highlights

Key Findings

• CMV DNAemia was detected in 11% of CMV-seropositive hospitalized COVID-19 patients by day 28, with higher incidence in more severe illness (OS 7: 24.7%).
• Risk factors for CMV DNAemia included older age, male sex, baseline disease severity, lymphopenia, and systemic corticosteroid use.
• Use of remdesivir and baricitinib did not influence the risk of CMV DNAemia.
• Presence of CMV DNAemia was independently associated with a 70% reduction in the probability of clinical improvement by day 29.
• Higher CMV viral loads correlated with more pronounced delays in recovery and were linked to increased SARS-CoV-2 viral loads.
• CMV DNAemia was associated with increased mortality in hospitalized adults with COVID-19 requiring oxygen support.

Clinical Implications

Clinicians should be aware that CMV reactivation occurs in a significant subset of hospitalized COVID-19 patients requiring oxygen and is linked to worse clinical outcomes. Monitoring for CMV DNAemia, especially in older males with lymphopenia and corticosteroid exposure, may identify patients at risk for delayed recovery and higher mortality. Current COVID-19 therapies such as remdesivir and baricitinib do not mitigate CMV reactivation risk, suggesting a potential need for targeted interventions in high-risk patients.

Conclusion

CMV DNAemia is a clinically relevant complication in hospitalized adults with COVID-19 requiring oxygen support, independently associated with delayed recovery, higher SARS-CoV-2 viral loads, and increased mortality. Recognition of CMV reactivation and its risk factors may inform prognosis and guide management strategies in this population.

References

1. NIAID ACTT-2 Trial Data -- Cytomegalovirus DNA Presence in Hospitalized Adults with SARS-CoV-2 Infection